You are here

  • Home
  • Archive
  • Volume 30, Issue 4
  • Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

Article metrics

Article menu
Download PDFPDF
Original research
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

 

Online download statistics by month:

Online download statistics by month: October 2021 to August 2024

AbstractFullPdf
Oct 202114611826
Nov 202145436
Dec 202131611
Jan 202223610
Feb 202220300
Mar 202218911
Apr 202231923
May 202228120
Jun 202223050
Jul 202218131
Aug 202222620
Sep 202222210
Oct 202221954
Nov 202229222
Dec 202218512
Jan 202320400
Feb 202318610
Mar 202318100
Apr 202313610
May 202313200
Jun 202338656
Jul 202331322
Aug 202330633
Sep 20236732
Oct 20233700
Nov 20235754
Dec 20238245
Jan 202411721
Feb 20247423
Mar 20248511
Apr 20249400
May 20249621
Jun 20248900
Jul 20246300
Aug 20245520
Total77748074